LivaNova PLC $LIVN Shares Bought by Capital Fund Management S.A.

Key Points

• Capital Fund Management S.A. increased its holdings in LivaNova PLC by 204.6%, owning 53,974 shares valued at $2.12 million as of its latest SEC filing.
• Several analysts have issued positive ratings for LivaNova, with price targets ranging from $58 to $64, indicating strong market confidence in the stock.
• LivaNova's shares rose 5.8% recently, reflecting a positive earnings report that surpassed analysts' expectations, with sales increasing by 10.6% year-over-year.

Capital Fund Management S.A. lifted its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 204.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 53,974 shares of the company's stock after acquiring an additional 36,256 shares during the period. Capital Fund Management S.A. owned 0.10% of LivaNova worth $2,120,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in LIVN. UMB Bank n.a. increased its position in LivaNova by 340.5% during the 1st quarter. UMB Bank n.a. now owns 837 shares of the company's stock valued at $33,000 after buying an additional 647 shares in the last quarter. CWM LLC increased its position in LivaNova by 52.3% during the 1st quarter. CWM LLC now owns 871 shares of the company's stock valued at $34,000 after buying an additional 299 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in LivaNova by 415.4% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company's stock valued at $58,000 after buying an additional 1,184 shares in the last quarter. Russell Investments Group Ltd. increased its position in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after buying an additional 219 shares in the last quarter. Finally, Central Pacific Bank Trust Division increased its position in LivaNova by 7.0% during the 1st quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock valued at $173,000 after buying an additional 290 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on LIVN. Barclays upped their target price on LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Robert W. Baird boosted their price target on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Wall Street Zen upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Needham & Company LLC reiterated a "buy" rating and set a $64.00 price target on shares of LivaNova in a research note on Tuesday, May 13th. Finally, Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a research note on Tuesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $59.71.

LivaNova Stock Performance

Shares of LIVN traded down $1.04 during mid-day trading on Thursday, reaching $55.45. The company had a trading volume of 445,519 shares, compared to its average volume of 706,575. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $57.35. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $3.03 billion, a P/E ratio of -14.25 and a beta of 0.92. The stock has a 50 day moving average of $47.11 and a two-hundred day moving average of $43.24.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The firm had revenue of $352.50 million for the quarter, compared to the consensus estimate of $332.20 million. During the same quarter in the prior year, the business earned $0.93 earnings per share. The company's revenue was up 10.6% compared to the same quarter last year. On average, analysts expect that LivaNova PLC will post 2.85 earnings per share for the current year.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.